Categories
Blood Cancer

Updated results of GRIFFIN: D-RVd vs RVd in patients with newly diagnosed multiple myeloma [Video]

Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, updates us on the findings from the Phase II GRIFFIN trial assessing the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (D-RVd) versus lenalidomide-bortezomib-dexamethasone (RVd) alone in patients with newly diagnosed multiple myeloma (NCT02874742). By the end of two years of maintenance therapy, the complete response (CR) rate was 79.8% in the D-RVd group vs 60.8% in the RVd group. Measurable residual disease (MRD) negativity and sustained MRD negativity were also significantly higher in the D-RVd arm. Interestingly, the rates of MRD negativity increased significantly from the end of the first year of maintenance therapy to the second year of maintenance therapy. Moreover, although the data is still premature and statistical significance for progression-free survival (PFS) has not yet been reached, there is a trend towards improved PFS in the daratumumab arm. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

GRIFFIN: subgroup analysis of patients with multiple myeloma with high-risk cytogenetics [Video]

Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, outlines the results of a subgroup analysis of the GRIFFIN trial (NCT02874742) investigating the efficacy of the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (D-RVd) in patients with multiple myeloma with high-risk cytogenetics. Dr Voorhees explains that adding 1q21 gain to the high-risk markers defined by IMWG criteria increases the study’s power which allows determining whether daratumumab provides a significant benefit to this patient population. After incorporating patients with 1q21 gain to the subgroup analysis, the study reported a trend towards an improved progression-free survival (PFS) for high-risk patients treated with D-RVd compared to RVd alone. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Antibodies in Multiple Myeloma: Insights and Patient Voices Along the Therapeutic Journey [Video]

Chair and Presenter, Suzanne Lentzsch, MD, PhD, Noa Biran, MD, and Ajay K. Nooka, MD, MPH, FACP, discuss multiple myeloma in this CME/MOC activity titled “A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/HYJ865. CME/MOC credit will be available until January 9, 2023.